Project Details
Abstract English
Diabetic nephropathy (DN) is a kidney-related complication that affects around 40% of type 1 and type 2
diabetic patients and is regarded as one of the most common causes of end-stage renal disease (ESRD)
worldwide. Despite currently being used as part of DN diagnosis, there is a great controversy over
albuminuria’s role as a surrogate end-point for the chronic kidney disease. In addition, other studies pointed that micro-albuminuria is not a precise predictor of DN risk as it showed considerable daily variation as its levels can be influenced by other conditions including exercise, certain types of diets, infections and high blood pressure. Urinary Exosomes have been proposed as a potential diagnostic biomarker for chronic kidney diseases. In our study, We aim to analyze the miRNA and protein content of urinary exosomes in DN patients at different disease stages and evaluate it’s use as a potential biomarker for DN diagnosis and prognosis. The availability of a sensitive and informative biomarker for DN that can early detect patients who will progress into ESRD would allow early intervention. In addition, as novel therapies for DN are being developed, there is a huge need for markers of disease progression that can be used to evaluate therapy response.
diabetic patients and is regarded as one of the most common causes of end-stage renal disease (ESRD)
worldwide. Despite currently being used as part of DN diagnosis, there is a great controversy over
albuminuria’s role as a surrogate end-point for the chronic kidney disease. In addition, other studies pointed that micro-albuminuria is not a precise predictor of DN risk as it showed considerable daily variation as its levels can be influenced by other conditions including exercise, certain types of diets, infections and high blood pressure. Urinary Exosomes have been proposed as a potential diagnostic biomarker for chronic kidney diseases. In our study, We aim to analyze the miRNA and protein content of urinary exosomes in DN patients at different disease stages and evaluate it’s use as a potential biomarker for DN diagnosis and prognosis. The availability of a sensitive and informative biomarker for DN that can early detect patients who will progress into ESRD would allow early intervention. In addition, as novel therapies for DN are being developed, there is a huge need for markers of disease progression that can be used to evaluate therapy response.
| Status | Active |
|---|---|
| Effective start/end date | 1/08/19 → 1/08/25 |
Collaborative partners
- Kuwait University
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.